tbuckley/cabot-search huggingface dataset:
Abstract 270: Micu1 Regulates Mitochondrial Structural Integrity and Cristae Function Independent of Mcu Calcium Uptake
Authors: Dhanendra Tomar, Manfred Thomas, Devin Kolmetzky, Oniel Salik, Joanne Garbincius, Pooja Jadiya, April C Carpenter, John W Elrod
Journal: Circulation Research (2020)

MICU1 is a Ca 2+ -sensor regulating the mitochondrial Ca 2+ uniporter channel (mtCU) and mitochondrial Ca 2+ uptake. MICU1 contains two Ca 2+ - binding EF-hand domains and directly interacts with the mtCU pore-forming subunit, MCU. MICU1-null mouse and fly models display perinatal lethality with disorganized mitochondrial architecture. Interestingly, these phenotypes are distinct from other mtCU loss-of-function models ( MCU, MICU2, EMRE, MCUR1 ) and thus are likely not explained solely by changes in matrix Ca 2+ content, suggesting MICU1 has cellular functions independent of the mtCU. To discern novel MICU1 molecular interactions we utilized a proximity-based biotinylation proteomic approach, BioID2, and expressed a MICU1-BioID2 fusion construct in wild-type and MCU -/- cells. LC-MS analysis of purified biotinylated proteins identified Mitochondrial Contact Site and Cristae Organizing System (MICOS) components MIC60, CHCHD2, and CHCHD3 as MICU1 interacting partners. Loss of MCU did not affect the MICU1-MICOS interaction, suggesting that MICU1 could be regulating the MICOS independent of the mtCU. Fast protein liquid chromatography (FPLC), blue native-PAGE, co-immunoprecipitation, live-cell Ca 2+ imaging, electron microscopy, confocal and super-resolution imaging confirmed that MICU1 (independent of matrix Ca 2+ ) is regulating mitochondrial membrane dynamics, membrane potential, and cell death signaling. Further, the deletion of Chchd2, a core component of the MICOS, resulted in disruption of cristae structure without any observable effect on mitochondrial Ca 2+ uptake. In addition, RNA sequencing of murine models of heart failure revealed a correlation between the expression of MICU1 and MICOS components and disease progression. These results are the first to identify how Ca 2+ regulates cristae structure and function and suggests MICU1, at the MICOS, regulates mitochondrial membrane remodeling in the context of cardiac stress and disease independent of the mtCU.
Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy
Authors: Maria Teresa Voso, Tatjana Pandzic, Michail Iskas, Marija Denčić-Fekete, Eleonora De Bellis, Lydia Scarfo, Viktor Ljungström, Giovanni Del Poeta, Pamela Ranghetti, Stamatia Laidou, Giulia Falconi, Silvia Imbergamo, Chiara Salvetti, Antonella Zucchetto, Niki Stavroyianni, Lucia Cavelier, Paolo Ghia, Kostas Stamatopoulos, Emiliano Fabiani, Panagiotis Baliakas
Journal: Blood (2020)
Abstract 10892: Sumoylation of Copper Chaperone Atox1 via Cysteine Oxidation of SENP1 as a Key Switch to Promote Atox1 Nuclear Translocation Driving Inflammation and Atherosclerosis
Authors: Archita Das, Sudhahar Varadarajan, David Fulton, Neal L Weintraub, Jun-ichi Abe, Masuko Ushio-Fukai, Tohru Fukai
Journal: Circulation (2019)

Introduction: Copper (Cu), essential nutrient, plays a role in inflammation and atherosclerosis with unknown mechanism. In inflamed endothelial cells (ECs), Cu chaperone Atox1 functions as a Cu-dep...
A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
Authors: Agnieszka Wierzbowska, Agnieszka Pluta, Marta Antonina Libura, Anna Czyz, Sebastian Giebel, Piotr Stelmach, Magdalena Czemerska, Anna Kopinska, Krzysztof Wozniczka, Grzegorz Helbig, Karol Wojcik, Malgorzata Razny, Marta Sobas, Tomasz Wrobel, Andrzej Szczepaniak, Lidia Gil, Alicja Sadowska-Klasa, Jan Zaucha, Tomasz Gromek, Marek Hus, Edyta Cichocka, Janusz Halka, Elzbieta Patkowska, Jolanta Wozniak, Agata Obara, Beata Blajer-Olszewska, Katarzyna Dulik, Jerzy Holowiecki, Michal Soin, Tadeusz Robak, Nicole M. Cruz, Nuria Mencia-Trinchant, Pinkal Desai, Sangmin Lee, Michael B. Samuel, Justin D. Kaner, Ellen Ritchie, Monica L. Guzman, Gail J. Roboz
Journal: Blood (2020)
Phenotypes of <i>JAK2</i>-Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study
Authors: Tony Hennersdorf, Nadja Jaekel, Susann Schulze, Dietrich Kaempfe, Claudia Spohn, Regina Moeller, Maik Schwarz, Hans-Juergen Hurtz, Joern Ruessel, Peter Tornow, Ute Neef, Marion Schmalfeld, Kathleen Jentsch-Ullrich, Thoralf Lange, Christian Junghanss, Brigitte Kragl, Haifa Kathrin Al-Ali
Journal: Blood (2020)
Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry
Authors: Adrienne Lee, Federico Germini, Man-Chiu Poon, Arun Keepanasseril, Quazi Ibrahim, Aijing Shang, Francis Nissen, Oliver Meier, Cami S. Sima, Davide Matino, Alfonso Iorio
Journal: Blood (2020)
A Multi-Center Case Series, Systematic Review and Meta-Analysis of Neonatal Hemophagocytic Lymphohistiocytosis
Authors: Christen L. Ebens, Adam S DuVall, Todd E. DeFor, Marketa T. Dimitrov, David Frame, Michael A. Briones, Michael Grimley, Sarita Joshi, Rebecca A. Marsh, Evan Shereck, Mark Vander Lugt, James A. Connelly, Kelly J. Walkovich
Journal: Blood (2020)
Doing the right thing and getting it right: professional perspectives in social work on supporting parents from gender diverse communities
Authors: Trish Hafford-Letchfield, Christine Cocker, Deborah Rutter, Rebecca Manning, Keira McCormack
Journal: International Journal of Transgender Health (2020)

Background Despite significant shifts in legislative, political, cultural and social contexts, which have improved our understanding of diverse gender identities and family life, this remains under-explored within social work and social care. Trans and non-binary (TNB) parenting experiences are marginalized within mainstream professional practice and action is required to address these inequalities.Aims This study explored the practices and meaning of 'parenting' and 'caring' for care professionals in families with parents with diverse gender identities in the UK. It aimed to capture a snapshot of the current state of practice knowledge and perceived practice challenges.Methods A qualitative study design involving thematic analysis from detailed consultation with twenty-five relevant stakeholders in the proxy roles identified from a systematic review on what is known about trans parenting from the research evidence.Results The complexity of systems for supporting families creates barriers to change, with a lack of training and development in the knowledge and skills of the workforce. Intersecting these themes was a strong values framework and examples of best practice provided, which social workers can use to navigate, understand, and support TNB parents and their experiences, particularly at an individual level, as a means to effect change.Discussion Focusing on human rights, tailoring work to the specific needs of individuals and families, and affirming the diversity of family life requires professionals to take active responsibility and be more accountable in educating themselves and others on these rights. Professionals also need to reach out to the TNB community to include them in improving services as well as being active in their own organizations to ensure these are inclusive and responsive.
Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B
Authors: Tyler W. Buckner, Shannon L Carpenter, Stacy E. Croteau, Adam Cuker, Nabil Daoud, Christine L Kempton, Lynn M Malec, Thomas W. McLean, Leslie J. Raffini, Janice M Staber, Michael Wang, Crystal Watson, Ayesha Zia, Michael Recht
Journal: Blood (2020)
Methscore As a New Prognostic Tool for Complex DNA Methylation Changes Assessment in Patients with Acute Myeloid Leukemia
Authors: Sarka Sestakova, Cyril Šálek, Dávid Kundrát, Ivana Ježíšková, Jiří Mayer, Zdeněk Ráčil, Petr Cetkovský, Hana Remešová
Journal: Blood (2020)
Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee
Authors: Antonio M. Jimenez, Trent Wang, Marcos de Lima, Krishna V Komanduri, Partow Kebriaei, Mark Litzow, Vijaya Raj Bhatt, Frédéric Baron, Ayman Saad, Nandita Khera, Joseph Maakaron, Hemant S. Murthy, Edward A Copelan, Zachariah Defilipp, Christopher Bredeson, Rodrigo Martino, Maxwell Krem, Taiga Nishihori, Mei-Jie Zhang, Daniel J. Weisdorf, Karen Chen, Wael Saber
Journal: Blood (2020)
Type I interferon signaling mediates <i>Mycobacterium tuberculosis</i>–induced macrophage death
Authors: Li Zhang, Xiuju Jiang, Daniel Pfau, Yan Ling, Carl F. Nathan
Journal: The Journal of Experimental Medicine (2020)

Macrophages help defend the host against Mycobacterium tuberculosis (Mtb), the major cause of tuberculosis (TB). Once phagocytized, Mtb resists killing by macrophages, replicates inside them, and leads to their death, releasing Mtb that can infect other cells. We found that the death of Mtb-infected mouse macrophages in vitro does not appear to proceed by a currently known pathway. Through genome-wide CRISPR-Cas9 screening, we identified a critical role for autocrine or paracrine signaling by macrophage-derived type I IFNs in the death of Mtb-infected macrophages in vitro, and blockade of type I IFN signaling augmented the effect of rifampin, a first-line TB drug, in Mtb-infected mice. Further definition of the pathway of type I IFN–mediated macrophage death may allow for host-directed therapy of TB that is more selective than systemic blockade of type I IFN signaling.
B-T Cell Interactions in GRAFT-Versus-Host Disease
Authors: Dhanya Kizhakayil, Abbirami Sathappan, Giusy Gentilcore, Zoltan Pos, Nikolett Lupsa, Mohammed A Al-Aghbar, Cristina Maccalli, Nicholas Van Panhuys, Jean-Charles Grivel, Sara Deola
Journal: Blood (2020)
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models
Authors: Nicholas A Vitanza, Matt C Biery, Carrie Myers, Eric Ferguson, Ye Zheng, Emily J Girard, Justyna M Przystal, Giulia Park, Alyssa Noll, Fiona Pakiam, Conrad A Winter, Shelli M Morris, Jay Sarthy, Bonnie L Cole, Sarah E S Leary, Courtney Crane, Nicole A P Lieberman, Sabine Mueller, Javad Nazarian, Raphael Gottardo, Mi-Youn Brusniak, Andrew J Mhyre, James M Olson
Journal: Neuro-Oncology (2020)

Abstract Background Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), have a dismal prognosis, with less than 2% surviving 5 years postdiagnosis. The majority of DIPGs and all DMGs harbor mutations altering the epigenetic regulatory histone tail (H3 K27M). Investigations addressing DMG epigenetics have identified a few promising drugs, including the HDAC inhibitor (HDACi) panobinostat. Here, we use clinically relevant DMG models to identify and validate other effective HDACi and their biomarkers of response. Methods HDAC inhibitors were tested across biopsy-derived treatment-naïve in vitro and in vivo DMG models with biologically relevant radiation resistance. RNA sequencing was performed to define and compare drug efficacy and to map predictive biomarkers of response. Results Quisinostat and romidepsin showed efficacy with low nanomolar half-maximal inhibitory concentration (IC50) values (~50 and ~5 nM, respectively). Comparative transcriptome analyses across quisinostat, romidepsin, and panobinostat showed a greater degree of shared biological effects between quisinostat and panobinostat, and less overlap with romidepsin. However, some transcriptional changes were consistent across all 3 drugs at similar biologically effective doses, such as overexpression of troponin T1 slow skeletal type (TNNT1) and downregulation of collagen type 20 alpha 1 chain (COL20A1), identifying these as potential vulnerabilities or on-target biomarkers in DMG. Quisinostat and romidepsin significantly (P &amp;lt; 0.0001) inhibited in vivo tumor growth. Conclusions Our data highlight the utility of treatment-naïve biopsy-derived models; establishes quisinostat and romidepsin as effective in vivo; illuminates potential mechanisms and/or biomarkers of DMG cell lethality due to HDAC inhibition; and emphasizes the need for brain tumor–penetrant versions of potentially efficacious agents.
ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility
Authors: Moritz Binder, Sandeep Potluri, Ryan M. Carr, Terra Lasho, Christy Finke, Abhishek A. Mangaonkar, Christopher Pin, Kurt Berger, Tamas Ordog, Bonnie Alver, Keith Robertson, David Marks, Martin Fernandez-Zapico, Alexandre Gaspar Maia, Mrinal M. Patnaik
Journal: Blood (2020)
The RNA Binding Protein IGF2BP3 Is Required for MLL-AF4 Mediated Leukemogenesis
Authors: Tiffany Tran, Jaspal Bassi, Neha Nibber, Julia Philipp, Jolene Draper, Tasha Lin, Jayanth Kumar Palanichamy, Amit Kumar, Oscar Silva, May Paing, Jennifer King, Sol Katzman, Jeremy Sanford, Dinesh S. Rao
Journal: Blood (2020)
Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry
Authors: Milena A. Gianfrancesco, Liza A. Leykina, Zara Izadi, Tiffany Taylor, Jeffrey A. Sparks, Carly Harrison, Laura Trupin, Stephanie Rush, Gabriela Schmajuk, Patricia Katz, Lindsay Jacobsohn, Tiffany Y. Hsu, Kristin M. D’Silva, Naomi Serling‐Boyd, Rachel Wallwork, Derrick J. Todd, Suleman Bhana, Wendy Costello, Rebecca Grainger, Jonathan S. Hausmann, Jean W. Liew, Emily Sirotich, Paul Sufka, Zachary S. Wallace, Pedro M. Machado, Philip C. Robinson, Jinoos Yazdany
Journal: Arthritis & Rheumatology (2020)

Racial/ethnic minorities experience more severe outcomes of coronavirus disease 2019 (COVID-19) in the general US population. This study was undertaken to examine the association between race/ethnicity and COVID-19 hospitalization, ventilation status, and mortality in people with rheumatic disease.US patients with rheumatic disease and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance physician registry between March 24, 2020 and August 26, 2020 were included. Race/ethnicity was defined as White, African American, Latinx, Asian, or other/mixed race. Outcome measures included hospitalization, requirement for ventilatory support, and death. Multivariable regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) adjusted for age, sex, smoking status, rheumatic disease diagnosis, comorbidities, medication use prior to infection, and rheumatic disease activity.A total of 1,324 patients were included, of whom 36% were hospitalized and 6% died; 26% of hospitalized patients required mechanical ventilation. In multivariable models, African American patients (OR 2.74 [95% CI 1.90-3.95]), Latinx patients (OR 1.71 [95% CI 1.18-2.49]), and Asian patients (OR 2.69 [95% CI 1.16-6.24]) had higher odds of hospitalization compared to White patients. Latinx patients also had 3-fold increased odds of requiring ventilatory support (OR 3.25 [95% CI 1.75-6.05]). No differences in mortality based on race/ethnicity were found, though power to detect associations may have been limited.Similar to findings in the general US population, racial/ethnic minorities with rheumatic disease and COVID-19 had increased odds of hospitalization and ventilatory support. These results illustrate significant health disparities related to COVID-19 in people with rheumatic diseases. The rheumatology community should proactively address the needs of patients currently experiencing inequitable health outcomes during the pandemic.
Blockade of Human PAR4 in Novel Humanized Mouse Strains Supports PAR4 As a Potential Target in Stroke: Ex Vivo Demonstration of Platelet Hyperreactivity of the Thr120 Variant
Authors: Robert A. Campbell, Michelle L. Stoller, Frederik Denorme, Bhanu Kanth Manne, Seema Bhatlekar, Emilia A Tugolukova, Paul F. Bray
Journal: Blood (2020)
Low vitamin D and risk of bacterial pneumonias: Mendelian randomisation studies in two population-based cohorts
Authors: Yunus Çolak, Børge G Nordestgaard, Shoaib Afzal
Journal: Thorax (2020)

Background Vitamin D may regulate the innate immune system, and randomised controlled trials suggest a beneficial effect of vitamin D supplementation against acute respiratory tract infections. By using a Mendelian randomisation approach, we tested the hypothesis that low 25-hydroxyvitamin D is associated with increased risk of bacterial pneumonia in observational and genetic analyses. Methods We genotyped 116 335 randomly chosen white Danes aged 20 to 100 from the Copenhagen City Heart Study and Copenhagen General Population Study for plasma 25-hydroxyvitamin D decreasing genetic variants around CYP2R1 (rs117913124, rs12794714 and rs10741657), DHCR7 (rs7944926 and rs11234027), GEMIN2 (rs2277458) and HAL (rs3819817). Information on plasma 25-hydroxyvitamin D was available on 35 833 individuals. Individuals were followed from 1981 through 2018 for hospital diagnoses of bacterial pneumonias. Results During up to 38 years follow-up, we observed 6342 bacterial pneumonias in observational analyses and 13 916 in genetic analyses. In observational analyses, multivariable adjusted HR for bacterial pneumonias was 1.27 (95% CI: 1.16 to 1.40) for individuals with 25-hydroxyvitamin D&lt;25 nmol/L compared with those with ≥25 nmol/L. In genetic analyses, the OR for bacterial pneumonia per 10 nmol/L lower plasma 25-hydroxyvitamin D was 1.12 (95% CI: 1.02 to 1.23) in Wald’s ratio, 1.12 (95% CI: 1.04 to 1.20) in inverse-variance weighted, 1.63 (95% CI: 0.96 to 2.78) in MR-Egger and 1.15 (95% CI: 1.05 to 1.26) in weighted median instrumental variable analysis. This association was strongest for genetic variants around CYP2R1 . There was no observational or genetic evidence to support that 25-hydroxyvitamin D is associated with risk of urinary tract infections, skin infections, sepsis or gastroenteritis, which were used as negative control outcomes. Conclusions Low vitamin D is associated observationally and genetically with increased risk of bacterial pneumonias.
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Authors: Malin Hultcrantz, Joshua Richter, Cara A. Rosenbaum, Dhwani Patel, Eric L. Smith, Neha Korde, Sydney X. Lu, Sham Mailankody, Urvi A. Shah, Alexander M. Lesokhin, Hani Hassoun, Carlyn Tan, Francesco Maura, Andriy Derkach, Benjamin Diamond, Adriana Rossi, Roger Pearse, Deepu Madduri, Ajai Chari, David Kaminetzky, Marc J. Braunstein, Christian Gordillo, Ran Reshef, Ying Taur, Faith E. Davies, Sundar Jagannath, Ruben Niesvizky, Suzanne Lentzsch, Gareth J. Morgan, Ola Landgren
Journal: Blood Cancer Discovery (2020)

[This corrects the article DOI: 10.1158/2643-3230.BCD-20-0102.].
Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms
Authors: Marcio M Andrade-Campos, Lierni Fernández-Ibarrondo, Joan Gibert, Concepción Fernández, Brayan Merchan, Nieves García Gisbert, Laura Camacho, Leonor Arenillas, Sara García Ávila, Raquel Longarón, Antonio Salar, Carles Besses, Beatriz Bellosillo
Journal: Blood (2020)
Abstract 529: A Modern Large-scale Analysis of Heart Transplantation in Elderly Patients
Authors: Manish Suryapalam, Mohammed Kashem, Val Rakita, Yoshiya Toyoda
Journal: Circulation Research (2020)

Introduction: As the prevalence of heart failure increases among older patients, the potential role of heart transplant (HTx) in this demographic demands further investigation. Survival outcome analysis of the elderly has primarily been analyzed in single-center studies, and the few long term studies performed have included a timeframe to the 1980s, introducing substantial variance from much poorer survival outcomes. We investigated the 5 to 10 year survival outcomes of more modern heart transplantation patients by analyzing the UNOS database. Methods: Heart transplantation data for 32,337 patients (2000-2014) was divided into three different age groups- &lt;60, 60-69, and ≥70 years old. Gender, ethnicity, height, weight, BMI, ICU stay, ischemic time, length of stay (LOS), and creatinine level were evaluated for significance using Chi-Squared and H-Tests as appropriate (p&lt;0.05). Survival outcome was assessed using a Kaplan-Meier Curve and log-rank tests. Results: 23,267 were &lt;60, 8,459 were 60-69, and 611 were ≥70, with mean ages of 38±0.1, 64±0.0, and 72±0.1 respectively. The distribution of gender, ethnicity, ischemic time, BMI, height, and weight was significantly different between the cohorts, with p=0.000 for all. Survival analysis indicated complete pairwise significance at 10 years post-HTx, with overall significance of p=0.000. At 5 years post-HTx, only 60-69 vs ≥70 did not have pairwise significance in survival. Conclusion: Contrary to prior studies, results indicate a statistically significant difference in survival the older and younger cohorts. This difference is especially prominent at the 10 th year post-transplant, but can be seen even at the 5 th year.
Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women
Authors: Giovanna Iantevi Ghelfond, Fernanda Santos, Fernanda S Seguro, Andre Abdo, Thales Pereira, Felipe VR Maciel, Lucas BO Alves, Israel Bendit, Vanderson Rocha, Eduardo M Rego
Journal: Blood (2020)
Efficacy and Safety of Lenalidomide, Rituximab Combined with Second-Line Chemotherapy (R2-chemo) in Patients with Relapsed/Refractory Diffuse Large-B Cell Lymphoma
Authors: Fei Xiao, Honghui Huang, Yanni Hua, Yi Fang, Minyue Zhang, Jian Hou
Journal: Blood (2020)
A Human Model of Down Syndrome Associated Leukemia Reveals Different Cell of Origins for Initiation and Progression
Authors: Elvin Wagenblast, Joana Araújo, Olga I. Gan, Sarah K Cutting, Alex Murison, Jessica L. McLeod, Gabriela Krivdova, Maria Azkanaz, Sabrina A Smith, Johann K Hitzler, John E. Dick, Eric R Lechman
Journal: Blood (2020)
Natural compounds modulate the autophagy with potential implication of stroke
Authors: Anil Ahsan, Mengru Liu, Yanrong Zheng, Wenping Yan, Ling Pan, Yue Li, Shijia Ma, Xingxian Zhang, Ming Cao, Zhanxun Wu, Weiwei Hu, Zhong Chen, Xiangnan Zhang
Journal: Acta Pharmaceutica Sinica B (2020)

Stroke is considered a leading cause of mortality and neurological disability, which puts a huge burden on individuals and the community. To date, effective therapy for stroke has been limited by its complex pathological mechanisms. Autophagy refers to an intracellular degrading process with the involvement of lysosomes. Autophagy plays a critical role in maintaining the homeostasis and survival of cells by eliminating damaged or non-essential cellular constituents. Increasing evidence support that autophagy protects neuronal cells from ischemic injury. However, under certain circumstances, autophagy activation induces cell death and aggravates ischemic brain injury. Diverse naturally derived compounds have been found to modulate autophagy and exert neuroprotection against stroke. In the present work, we have reviewed recent advances in naturally derived compounds that regulate autophagy and discussed their potential application in stroke treatment.